by Ariana | Sep 26, 2025 | Article
New Hope in Lupus Research: Biogen’s Promising Treatments Biogen, a company known for its work in autoimmune diseases, is developing two new medicines for lupus: litifilimaband dapirolizumab pegol. Both medicines are in late-stage clinical trials, and early results...
by Ariana | Jun 6, 2025 | Article
Expanded Access for Adults with Moderate to Severe Systemic Lupus Erythematosus: Anifrolumab is now listed under BC PharmaCare’s Limited Coverage drug formulary. Learn More Anifrolumab (Saphnelo) is now listed under BC PharmaCare’s Limited Coverage drug formulary,...
by Ariana | Jun 3, 2025 | Article
Belimumab Approved for Lupus Nephritis: A New Hope for Patients Learn More Belimumab for lupus nephritis in BC is now publicly funded under the BC Renal Glomerulonephritis (GN) Formulary as of May 2025. This marks a significant step forward in improving access to care...
by Ariana | Apr 15, 2025 | Article
Understanding Lupus Care & Access Across Provinces in Canada Take the Survey Participate in Our National Lupus Treatment Access Survey Join us in our mission to improve access to lupus treatment across Canada. This national survey aims to understand the challenges...
by Ariana | Mar 31, 2025 | Article
Understanding the Canada Disability Benefit Canada Disability Benefit Regulations Finalized The Government of Canada has finalized the Canada Disability Benefit (CDB) Regulations, which are set to take effect on May 15, 2025. Learn More What Is the Canada Disability...
